<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetol Metab Syndr</journal-id><journal-id journal-id-type="iso-abbrev">Diabetol Metab Syndr</journal-id><journal-title-group><journal-title>Diabetology &#x00026; Metabolic Syndrome</journal-title></journal-title-group><issn pub-type="epub">1758-5996</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27660663</article-id><article-id pub-id-type="pmc">5027076</article-id><article-id pub-id-type="publisher-id">163</article-id><article-id pub-id-type="doi">10.1186/s13098-016-0163-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Rojas</surname><given-names>Arturo</given-names></name><address><phone>01-52-9212128932</phone><email>rojasarturo0958@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sposetti</surname><given-names>Georgina</given-names></name><address><email>gsposetti@iic-mardelplata.com.ar</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gross</surname><given-names>Jorge L.</given-names></name><address><email>jorgeluizgross@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Barbieri</surname><given-names>Douglas Eugenio</given-names></name><address><email>douglasbarbieri@uol.com.br</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Duan</surname><given-names>Ran</given-names></name><address><email>Duan_ran@lilly.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Linetzky</surname><given-names>Bruno</given-names></name><address><email>linetzky_bruno@lilly.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>De Lana</surname><given-names>Janaina Martins</given-names></name><address><email>jlana@lilly.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Stempa</surname><given-names>Oded</given-names></name><address><email>stempa_blumenfeld_oded@lilly.com</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Rodriguez</surname><given-names>Angel</given-names></name><address><email>rodriguez_angel@lilly.com</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label>Direccion-investigacion, Servicio Medico Nutricional S.C. (Centro de Diabetes de Coatzacoalcos), Revolucion # 522, 96400 Coatzacoalcos, VER M&#x000e9;xico </aff><aff id="Aff2"><label>2</label>Diabetes and Metabolism Research Department, Head en Instituto de Investigaciones Cl&#x000ed;nicas, Mar del Plata, Argentina </aff><aff id="Aff3"><label>3</label>Centro de Pesquisas em Diabetes, Porto Alegre, Rio Grande do Sul Brazil </aff><aff id="Aff4"><label>4</label>Eli Lilly do Brasil Ltda, S&#x000e3;o Paulo, Brazil </aff><aff id="Aff5"><label>5</label>Eli Lilly, Indianapolis, USA </aff><aff id="Aff6"><label>6</label>Eli Lilly Interamerica Inc., Buenos Aires, Argentina </aff><aff id="Aff7"><label>7</label>Eli Lilly and Co, M&#x000e9;xico City, M&#x000e9;xico </aff><aff id="Aff8"><label>8</label>Lilly Spain, Alcobendas, Spain </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>8</volume><elocation-id>69</elocation-id><history><date date-type="received"><day>9</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>10</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>This post hoc analysis examined the efficacy and safety of twice-daily insulin lispro low mixture (LM25) and once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL) in a Latin American subpopulation with type 2 diabetes mellitus (T2DM).</p></sec><sec><title>Methods</title><p>A phase 4, randomized, open-label, parallel-arm trial included participants aged 18&#x02013;75&#x000a0;years with T2DM taking once-daily insulin glargine and stable doses of metformin and/or pioglitazone with glycated hemoglobin (HbA1c) 7.5&#x02013;10.5&#x000a0;% and fasting plasma glucose&#x000a0;&#x02264;121&#x000a0;mg/dL. Participants were randomized 1:1 to receive their stable dose of metformin and/or pioglitazone plus twice-daily LM25 or IGL for 24&#x000a0;weeks. The primary efficacy outcome was change in HbA1c after 24&#x000a0;weeks of treatment. Results from participants in Argentina, Brazil, and Mexico are presented here.</p></sec><sec><title>Results</title><p>162 participants (80 LM25; 82 IGL) with mean&#x000a0;&#x000b1;&#x000a0;standard deviation (SD) age&#x000a0;=&#x000a0;57.3&#x000a0;&#x000b1;&#x000a0;9.0&#x000a0;years and body mass index&#x000a0;=&#x000a0;31.3&#x000a0;&#x000b1;&#x000a0;5.2&#x000a0;kg/m<sup>2</sup> were included. Mean&#x000a0;&#x000b1;&#x000a0;SD change in HbA1c from baseline to week 24 was &#x02212;1.5&#x000a0;&#x000b1;&#x000a0;1.0&#x000a0;% (LM25) and &#x02212;1.1&#x000a0;&#x000b1;&#x000a0;1.2&#x000a0;% (IGL). At week 24, 35.1&#x000a0;% (LM25) and 31.6&#x000a0;% (IGL) of participants achieved HbA1c&#x000a0;&#x0003c;7.0&#x000a0;%. Mean&#x000a0;&#x000b1;&#x000a0;SD weight gain from baseline to week 24 was 2.4&#x000a0;&#x000b1;&#x000a0;2.9&#x000a0;kg in the LM25 group and 1.0&#x000a0;&#x000b1;&#x000a0;3.1&#x000a0;kg in the IGL group. The mean&#x000a0;&#x000b1;&#x000a0;SD rates of total hypoglycemia per year were 18.9&#x000a0;&#x000b1;&#x000a0;27.3 (LM25) and 21.6&#x000a0;&#x000b1;&#x000a0;31.1&#x000a0;(IGL). Rates of treatment-emergent adverse events were 46&#x000a0;% (LM25) and 39&#x000a0;% (IGL).</p></sec><sec><title>Conclusions</title><p>Our results suggest that both LM25 and IGL are viable treatment options for insulin intensification in Latin American patients with T2DM with suboptimal glycemic control on basal insulin glargine. The safety and tolerability profiles of LM25 and IGL are consistent between this Latin American population and the global trial-level population.</p><p><italic>Trial registration</italic> NCT01175824</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Diabetes mellitus, type 2</kwd><kwd>Insulin intensification</kwd><kwd>Insulin lispro</kwd><kwd>Insulin lispro mixture</kwd><kwd>Latin America</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004312</institution-id><institution>Eli Lilly and Company</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Type 2 diabetes mellitus (T2DM) is an important health problem in Latin America, particularly in Brazil and Mexico, which respectively have the fourth and sixth largest populations of people with diabetes in the world [<xref ref-type="bibr" rid="CR1">1</xref>]. In 2014, the prevalence of T2DM in South and Central America was 8.1&#x000a0;% (24.8 million patients) [<xref ref-type="bibr" rid="CR2">2</xref>] and is projected to increase by 60&#x000a0;% (to 38.5 million patients) by 2035 [<xref ref-type="bibr" rid="CR1">1</xref>]. This increase is partly caused by changes in diet and lifestyle, e.g., urbanization, an increase in the consumption of animal products and processed foods, and increases in patient body mass [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. Moreover, only 36&#x000a0;% of patients with T2DM in Latin America and only 26&#x000a0;% in Brazil have a glycated hemoglobin level (HbA1c) at the recommended level of&#x000a0;&#x0003c;7.0&#x000a0;% [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Considering the changing lifestyle and the increasing prevalence of T2DM in the region, current scientific evidence on insulin intensification strategies from global populations must be verified in a Latin American population.</p><p>As T2DM progresses, there is a decline in insulin secretory capacity such that, for most patients, treatment with insulin must be initiated to achieve the target HbA1c&#x000a0;&#x02264;7&#x000a0;% [<xref ref-type="bibr" rid="CR8">8</xref>]. The Latin American Diabetes Association (ALAD) guidelines recommend initiating insulin therapy with a long-acting basal insulin analogue, such as insulin glargine, in combination with oral agents for patients who fail to achieve target HbA1c on oral agents alone [<xref ref-type="bibr" rid="CR3">3</xref>]. Unfortunately, the long-term efficacy of basal insulin therapy alone is often limited [<xref ref-type="bibr" rid="CR9">9</xref>], with less than 50&#x000a0;% of patients reaching target HbA1c, commonly due to excessive postprandial glycemic excursions [<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, most patients with T2DM will require an intensification of their insulin therapy.</p><p>The ALAD guidelines recommend intensifying insulin therapy with a combination of 2 types of insulin [<xref ref-type="bibr" rid="CR3">3</xref>]. To this end, there are 2 possible strategies for intensifying insulin therapy: switching to a premixed combination of long-acting and short-acting insulin administered twice daily [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR10">10</xref>] or continuing on basal insulin and adding rapid-acting insulin before meals [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. There are few data directly comparing these 2 insulin intensification strategies in Latin American patients with T2DM inadequately controlled by basal insulin plus oral antidiabetic agents. This post hoc analysis of a multinational clinical trial compared the efficacy and safety of twice-daily insulin lispro low mixture (LM25) and once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL) in Latin American patients with T2DM who had not achieved target HbA1c on once-daily basal insulin glargine with metformin and/or pioglitazone.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>This study was a post hoc analysis of a subpopulation of Latin American participants from a multinational, randomized, open-label, noninferiority, phase 4 clinical trial designed to examine the efficacy and safety of 2 insulin intensification strategies in patients with T2DM not adequately controlled on once-daily basal insulin glargine with metformin and/or pioglitazone [<xref ref-type="bibr" rid="CR12">12</xref>]. The global study was approved by an independent ethical review board at each study site and was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice standards, and all local laws and regulations in the study countries. The trial was registered with ClinicalTrials.gov: NCT01175824. All participants provided written informed consent.</p></sec><sec id="Sec4"><title>Study population</title><p>In the global study, participants were enrolled at 55 study sites in Argentina, Brazil, China, Egypt, India, Republic of Korea, M&#x000e9;xico, Romania, Russian Federation, Spain, and Turkey. This post hoc analysis included data from participants who were enrolled in Latin America (Argentina, Brazil, and Mexico).</p><p>The inclusion criteria were: age 18&#x02013;75&#x000a0;years; a diagnosis of T2DM consistent with the World Health Organization Classification of Diabetes [<xref ref-type="bibr" rid="CR13">13</xref>]; HbA1c 7.5&#x02013;10.5&#x000a0;%; current regimen of stable doses of metformin (&#x02265;1500&#x000a0;mg/day for at least 8&#x000a0;weeks) and/or pioglitazone (&#x02265;30&#x000a0;mg/day for at least 12&#x000a0;weeks); a current stable regimen of once-daily basal insulin glargine for at least 90&#x000a0;days before screening; and fasting plasma glucose&#x000a0;&#x02264;121&#x000a0;mg/dL, determined by the central laboratory, or&#x000a0;&#x0003e;121&#x000a0;mg/dL if the investigator determined further titration of basal insulin glargine was not possible for safety reasons. Exclusion criteria were: a screening body mass index&#x000a0;&#x0003e;45&#x000a0;kg/m<sup>2</sup>; more than 1 severe hypoglycemic episode within 24&#x000a0;weeks before screening; and a history of using drugs contraindicated for use with the study drugs.</p><p>At the screening visit, demographic and clinical data were collected from all participants. Participants also underwent a physical examination and provided a fasting plasma glucose (FPG) sample for measurement in a central laboratory.</p></sec><sec id="Sec5"><title>Treatment protocol</title><p>The trial treatment protocol has been described in detail previously [<xref ref-type="bibr" rid="CR12">12</xref>]. Briefly, participants were randomized to receive subcutaneous twice-daily LM25 (insulin lispro low mixture; 75&#x000a0;% insulin lispro protamine suspension and 25&#x000a0;% insulin lispro solution) or IGL (once-daily basal insulin glargine and once-daily prandial insulin lispro), in addition to their stable dose of metformin and/or pioglitazone, for 24&#x000a0;weeks. LM25 was administered before breakfast and dinner. Insulin glargine was administered at bedtime. Insulin lispro was administered before the largest meal of the day. The largest meal of the day was defined as the meal with the highest 2-h postprandial blood glucose concentration and was determined during the screening period. LM25, insulin glargine, and insulin lispro were administered using 100&#x000a0;U/mL prefilled pens.</p></sec><sec id="Sec6"><title>Outcome measures</title><p>The primary efficacy endpoint was the change in HbA1c from baseline to week 24. The secondary efficacy endpoints were the percentage of participants reaching the HbA1c target levels&#x000a0;&#x0003c;7.0 and&#x000a0;&#x02264;6.5&#x000a0;%, the change in FPG concentration from baseline to week 24, 7-point self-monitoring of blood glucose (SMBG) profiles at baseline and week 24, glycemic variability at week 24 [as measured by the standard deviation (SD)] in 7-point SMBG profiles, daily total, basal, and prandial insulin doses at week 24, and change in body weight at week 24.</p><p>Safety endpoints included treatment-emergent adverse events (TEAEs), and the incidence, rate, and severity of hypoglycemic episodes. In addition, participant satisfaction with insulin treatment was measured using the insulin treatment satisfaction questionnaire (ITSQ) [<xref ref-type="bibr" rid="CR14">14</xref>]. Participant perceptions about the acceptability and effectiveness of diabetes medications and perceived adverse effects were measured using the perceptions about medications-diabetes 21 (PAM-D21) questionnaire [<xref ref-type="bibr" rid="CR15">15</xref>]. Total scores on the ITSQ range from 0 to 100, where 100 indicates complete satisfaction with insulin treatment. Subscale scores on the PAM-D21 range from 0 to 100, where higher scores indicate better perceptions about diabetes medications.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p>The intent-to-treat (ITT) and safety populations were both defined as all randomized participants who received at least 1 dose of study drug. Efficacy and health outcome endpoints were analyzed using the ITT population. Summary statistics were calculated by treatment group for all endpoints. Due to the relatively small sample size, no statistical comparisons were made between treatment groups.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Participant disposition</title><p>A total of 248 patients were screened for study entry in Latin America. Of these, 162 were eligible for inclusion in the study and received at least 1 dose of study drug, 12 discontinued, and 150 completed the study (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Participant disposition. Summary of participant disposition of Latin American participants with type 2 diabetes mellitus who were treated with LM25 or IGL for 24&#x000a0;weeks. <italic>IGL</italic>&#x000a0;once-daily basal insulin glargine plus&#x000a0;once-daily prandial insulin lispro, <italic>LM25</italic>&#x000a0;75&#x000a0;% insulin lispro protamine suspension and 25&#x000a0;% insulin lispro solution</p></caption><graphic xlink:href="13098_2016_163_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec10"><title>Baseline characteristics</title><p>Baseline demographic and clinical characteristics are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Demographic and baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">LM25 (N&#x000a0;=&#x000a0;80)</th><th align="left">IGL (N&#x000a0;=&#x000a0;82)</th><th align="left">Total (N&#x000a0;=&#x000a0;162)</th></tr></thead><tbody><tr><td align="left" colspan="4">Country, n (%)</td></tr><tr><td align="left">&#x000a0;Argentina</td><td char="(" align="char">40 (50.0)</td><td char="(" align="char">39 (47.6)</td><td char="(" align="char">79 (48.8)</td></tr><tr><td align="left">&#x000a0;Brazil</td><td char="(" align="char">20 (25.0)</td><td char="(" align="char">23 (28.0)</td><td char="(" align="char">43 (26.5)</td></tr><tr><td align="left">&#x000a0;Mexico</td><td char="(" align="char">20 (25.0)</td><td char="(" align="char">20 (24.4)</td><td char="(" align="char">40 (24.7)</td></tr><tr><td align="left" colspan="4">Sex, n (%)</td></tr><tr><td align="left">&#x000a0;Male</td><td char="(" align="char">39 (48.8)</td><td char="(" align="char">30 (36.6)</td><td char="(" align="char">69 (42.6)</td></tr><tr><td align="left">&#x000a0;Female</td><td char="(" align="char">41 (51.3)</td><td char="(" align="char">52 (63.4)</td><td char="(" align="char">93 (57.4)</td></tr><tr><td align="left">Age (years), mean (SD)</td><td char="(" align="char">57.5 (9.7)</td><td char="(" align="char">57.1 (8.4)</td><td char="(" align="char">57.3 (9.0)</td></tr><tr><td align="left">Weight (kg), mean (SD)</td><td char="(" align="char">82.5 (15.4</td><td char="(" align="char">81.8 (15.0)</td><td char="(" align="char">82.2 (15.1)</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>), mean (SD)</td><td char="(" align="char">30.9 (4.8)</td><td char="(" align="char">31.7 (5.5)</td><td char="(" align="char">31.3 (5.2)</td></tr><tr><td align="left">Duration of diabetes (years), mean (SD)</td><td char="(" align="char">13.8 (7.9)</td><td char="(" align="char">12.9 (6.8)</td><td char="(" align="char">13.4 (7.3)</td></tr><tr><td align="left" colspan="4">HbA1c at screening</td></tr><tr><td align="left">&#x000a0;%, mean (SD)</td><td char="(" align="char">8.8 (0.8)</td><td char="(" align="char">8.6 (0.8)</td><td char="(" align="char">8.7 (0.8)</td></tr><tr><td align="left">&#x000a0;&#x0003c;8.5&#x000a0;%, n (%)</td><td char="(" align="char">33 (41.3)</td><td char="(" align="char">35 (42.7)</td><td char="(" align="char">68 (42.0)</td></tr><tr><td align="left">FPG (mg/dL), mean (SD)</td><td char="(" align="char">107.1 (37.1)</td><td char="(" align="char">98.5 (28.2)</td><td char="(" align="char">102.8 (33.0)</td></tr><tr><td align="left">Insulin glargine dose at screening (IU), &#x000a0;mean (SD)</td><td char="(" align="char">39.3 (19.3)</td><td char="(" align="char">39.5 (18.9)</td><td char="(" align="char">39.4 (19.0)</td></tr><tr><td align="left">Glycemic variability (mg/dL), mean (SD)</td><td char="(" align="char">46.6 (18.8)</td><td char="(" align="char">49.7 (18.6)</td><td char="(" align="char">48.2 (18.7)</td></tr><tr><td align="left" colspan="4">Concomitant oral antidiabetic drugs</td></tr><tr><td align="left">&#x000a0;Metformin, n (%)</td><td char="(" align="char">80 (100)</td><td char="(" align="char">82 (100)</td><td char="(" align="char">162 (100)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Daily dose (mg), mean (SD)</td><td char="(" align="char">1968.1 (393.0)</td><td char="(" align="char">2062.8 (396.8)</td><td char="(" align="char">2016.0 (396.6)</td></tr><tr><td align="left">&#x000a0;Pioglitazone, n (%)</td><td char="(" align="char">4 (5.0)</td><td char="(" align="char">5 (6.1)</td><td char="(" align="char">9 (5.6)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Daily dose (mg), mean (SD)</td><td char="(" align="char">30.0 (0.0)</td><td char="(" align="char">30.0 (0.0)</td><td char="(" align="char">30.0 (0.0)</td></tr><tr><td align="left">&#x000a0;Metformin and pioglitazone, n (%)</td><td char="(" align="char">4 (5.0)</td><td char="(" align="char">5 (6.1)</td><td char="(" align="char">9 (5.6)</td></tr></tbody></table><table-wrap-foot><p>
<italic>BMI</italic>&#x000a0;body mass index, <italic>FPG</italic>&#x000a0;fasting plasma glucose, <italic>HbA1c</italic>&#x000a0;glycated hemoglobin, <italic>IGL</italic>&#x000a0;once-daily basal insulin glargine plus once-daily prandial insulin lispro, <italic>IU</italic>&#x000a0;international units, <italic>LM25</italic>&#x000a0;75&#x000a0;% insulin lispro protamine suspension and 25&#x000a0;% insulin lispro solution, <italic>SD</italic>&#x000a0;standard deviation</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Efficacy</title><p>With respect to the primary outcome, the mean&#x000a0;&#x000b1;&#x000a0;SD change in HbA1c from baseline to week 24 was &#x02212;1.5&#x000a0;&#x000b1;&#x000a0;1.0&#x000a0;% in the LM25 group and &#x02212;1.1&#x000a0;&#x000b1;&#x000a0;1.2&#x000a0;% in the IGL group. The mean&#x000a0;&#x000b1;&#x000a0;SD change in HbA1c from baseline to week 12 was &#x02212;1.4&#x000a0;&#x000b1;&#x000a0;1.0&#x000a0;% in the LM25 group and &#x02212;1.1&#x000a0;&#x000b1;&#x000a0;1.1&#x000a0;% in the IGL group. The observed HbA1c levels throughout the study are presented in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>HbA1c levels in participants receiving LM25 or IGL. Observed HbA1c levels at baseline, week 12, and week&#x000a0;24 in participants receiving LM25 or IGL. Values in <italic>boxes</italic> denote mean HbA1c. <italic>HbA1c</italic>&#x000a0;glycated hemoglobin, <italic>IGL</italic>&#x000a0;once-daily basal insulin glargine plus&#x000a0;once-daily prandial insulin lispro, <italic>LM25</italic>&#x000a0;75&#x000a0;% insulin lispro protamine suspension and 25&#x000a0;% insulin lispro solution</p></caption><graphic xlink:href="13098_2016_163_Fig2_HTML" id="MO2"/></fig></p><p>A total of 35.1&#x000a0;% (26/74) of participants in the LM25 group and 31.6&#x000a0;% (24/76) of participants in the IGL group achieved HbA1c&#x000a0;&#x02264;7.0&#x000a0;%. A total of 14.9&#x000a0;% (11/74) of participants in the LM25 group and 15.8&#x000a0;% (12/76) of participants in the IGL group achieved HbA1c&#x000a0;&#x02264;6.5&#x000a0;%.</p><p>The mean&#x000a0;&#x000b1;&#x000a0;SD FPG at week 24 was 125.5&#x000a0;&#x000b1;&#x000a0;42.9&#x000a0;mg/dL in the LM25 group and 121.0&#x000a0;&#x000b1;&#x000a0;39.9&#x000a0;mg/dL in the IGL group. The mean&#x000a0;&#x000b1;&#x000a0;SD change in FPG from baseline to week 24 was 17.6&#x000a0;&#x000b1;&#x000a0;55.2&#x000a0;mg/dL in the LM25 group and 21.6&#x000a0;&#x000b1;&#x000a0;46.9&#x000a0;mg/dL in the IGL group. The mean&#x000a0;&#x000b1;&#x000a0;SD glycemic variability at baseline was 46.6&#x000a0;&#x000b1;&#x000a0;18.8 in the LM25 group and 49.7&#x000a0;&#x000b1;&#x000a0;18.6 in the IGL group. The mean&#x000a0;&#x000b1;&#x000a0;SD changes in glycemic variability from baseline to week 24 were &#x02212;9.0&#x000a0;&#x000b1;&#x000a0;17.3&#x000a0;mg/dL (LM25) and &#x02212;10.4&#x000a0;&#x000b1;&#x000a0;17.9&#x000a0;mg/dL (IGL).</p><p>The mean unadjusted 7-point SMBG levels at baseline and week 24 are presented in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>7-point SMBG levels at baseline and week 24. Mean unadjusted 7-point SMBG levels at baseline and week 24 in Latin American participants with type 2 diabetes mellitus who were treated with LM25 or IGL for 24&#x000a0;weeks. <italic>Error bars</italic> indicate standard deviation. <italic>IGL</italic>&#x000a0;once-daily basal insulin glargine plus&#x000a0;once-daily prandial insulin lispro, <italic>LM25</italic>&#x000a0;75&#x000a0;% insulin lispro protamine suspension and 25&#x000a0;% insulin lispro solution, <italic>SMBG</italic>&#x000a0;self-monitoring of blood glucose</p></caption><graphic xlink:href="13098_2016_163_Fig3_HTML" id="MO3"/></fig></p><p>Total daily, basal, and prandial insulin doses at baseline and week 24 are presented in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Of the patients in the IGL group, 10 received prandial insulin lispro at breakfast, 40 at lunch, and 32 at dinner.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Total daily, basal, and prandial insulin doses at baseline and week 24</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Insulin dose</th><th align="left">LM25&#x000a0;(N&#x000a0;=&#x000a0;80)</th><th align="left">IGL (N&#x000a0;=&#x000a0;82)</th></tr></thead><tbody><tr><td align="left" colspan="3">Total daily insulin dose (IU), mean (SD)</td></tr><tr><td align="left">&#x000a0;Baseline<sup>a</sup>
</td><td char="(" align="char">40.0 (19.2)</td><td char="(" align="char">43.9 (18.8)</td></tr><tr><td align="left">&#x000a0;Week 24</td><td char="(" align="char">61.0 (27.6)</td><td char="(" align="char">60.6 (24.3)</td></tr><tr><td align="left" colspan="3">Daily basal insulin dose (IU), mean (SD)</td></tr><tr><td align="left">&#x000a0;Baseline<sup>a</sup>
</td><td char="(" align="char">30.0 (14.4)</td><td char="(" align="char">39.8 (18.8)</td></tr><tr><td align="left">&#x000a0;Week 24</td><td char="(" align="char">45.8 (20.7)</td><td char="(" align="char">46.3 (20.2)</td></tr><tr><td align="left" colspan="3">Daily prandial insulin dose (IU), mean (SD)</td></tr><tr><td align="left">&#x000a0;Baseline<sup>a</sup>
</td><td char="(" align="char">10.0 (4.8)</td><td char="(" align="char">4.2 (0.8)</td></tr><tr><td align="left">&#x000a0;Week 24</td><td char="(" align="char">15.3 (6.9)</td><td char="(" align="char">14.4 (6.6)</td></tr></tbody></table><table-wrap-foot><p>
<italic>IGL</italic>&#x000a0;once-daily basal insulin glargine plus once-daily prandial insulin lispro, <italic>IU</italic>&#x000a0;international units, <italic>LM25</italic>&#x000a0;75&#x000a0;% insulin lispro protamine suspension and 25&#x000a0;% insulin lispro solution, <italic>SD</italic>&#x000a0;standard deviation</p><p>
<sup>a</sup>Baseline in this table is defined as day 1 post-randomization</p></table-wrap-foot></table-wrap></p><p>Participants in both treatment groups experienced weight gain. The mean&#x000a0;&#x000b1;&#x000a0;SD changes in body weight from baseline to week 24 were 2.4&#x000a0;&#x000b1;&#x000a0;2.9&#x000a0;kg (LM25) and 1.0&#x000a0;&#x000b1;&#x000a0;3.1&#x000a0;kg (IGL).</p></sec><sec id="Sec12"><title>Safety and tolerability</title><p>At least 1 TEAE was reported by 46&#x000a0;% (37/80) of participants in the LM25 group and 39&#x000a0;% (32/82) of participants in the IGL group. Of these, 7.5&#x000a0;% (6/80) of participants in the LM25 group and 4.9&#x000a0;% (4/82) of participants in the IGL group reported TEAEs that were considered to possibly be related to the study drugs. Serious TEAEs were reported by 3.8&#x000a0;% (3/80) of participants in the LM25 group and 3.7&#x000a0;% (3/82) of participants in the IGL group. One participant in each group discontinued due to adverse events and no participants died during the study.</p><p>Overall, approximately 70&#x000a0;% (113/162) of participants experienced at least 1 episode of hypoglycemia during the study (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Severe hypoglycemia was experienced by 1.3&#x000a0;% (1/80) of participants in the LM25 group and no participants in the IGL group.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Reported hypoglycemia in study participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Hypoglycemia</th><th align="left" colspan="2">LM25&#x000a0; (N&#x000a0;=&#x000a0;80)</th><th align="left" colspan="2">IGL (N&#x000a0;=&#x000a0;82)</th></tr><tr><th align="left">Participants with&#x000a0;&#x02265;1 episode,<break/>n (%)</th><th align="left">Number of episodes per participant year,<break/>mean (SD)</th><th align="left">Participants with&#x000a0;&#x02265;1 episode,<break/>n (%)</th><th align="left">Number of episodes per participant year,<break/>mean (SD)</th></tr></thead><tbody><tr><td align="left">Overall (&#x02264;70&#x000a0;mg/dL)</td><td char="(" align="char">57 (71.3)</td><td char="(" align="char">18.9 (27.3)</td><td char="(" align="char">56 (68.3)</td><td char="(" align="char">21.6 (31.1)</td></tr><tr><td align="left">Documented symptomatic (&#x02264;70&#x000a0;mg/dL)</td><td char="(" align="char">45 (56.3)</td><td char="(" align="char">9.6 (15.5)</td><td char="(" align="char">40 (48.8)</td><td char="(" align="char">11.0 (19.4)</td></tr><tr><td align="left">Asymptomatic (&#x02264;70&#x000a0;mg/dL)</td><td char="(" align="char">36 (45.0)</td><td char="(" align="char">8.5 (17.9)</td><td char="(" align="char">43 (52.4)</td><td char="(" align="char">10.2 (20.9)</td></tr><tr><td align="left">Nocturnal</td><td char="(" align="char">24 (30.0)</td><td char="(" align="char">2.4 (5.8)</td><td char="(" align="char">22 (26.8)</td><td char="(" align="char">2.8 (6.5)</td></tr><tr><td align="left">Severe</td><td char="(" align="char">1 (1.3)</td><td char="(" align="char">0.1 (0.7)</td><td char="(" align="char">0 (0)</td><td char="(" align="char">0 (0)</td></tr></tbody></table><table-wrap-foot><p>
<italic>IGL</italic>&#x000a0;once-daily basal insulin glargine plus once-daily prandial insulin lispro, <italic>LM25</italic>&#x000a0;75&#x000a0;% insulin lispro protamine suspension and 25&#x000a0;% insulin lispro solution, <italic>SD</italic>&#x000a0;standard deviation</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Health outcomes</title><p>The mean changes in ITSQ and PAM-D21 from baseline to week 24 are presented in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Changes in ITSQ and PAM-D21 questionnaire scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variable, change from baseline</th><th align="left" colspan="2">LM25 (N&#x000a0;=&#x000a0;80)</th><th align="left" colspan="2">IGL (N&#x000a0;=&#x000a0;82)</th></tr><tr><th align="left">Baseline</th><th align="left">Change from baseline</th><th align="left">Baseline</th><th align="left">Change from baseline</th></tr></thead><tbody><tr><td align="left" colspan="5">ITSQ, mean (SD)</td></tr><tr><td align="left">&#x000a0;Inconvenience of regimen</td><td char="(" align="char">92.7 (10.7)</td><td char="(" align="char">&#x02212;1.5 (11.0)</td><td char="(" align="char">92.2 (12.1)</td><td char="(" align="char">0.5 (11.2)</td></tr><tr><td align="left">&#x000a0;Lifestyle flexibility</td><td char="(" align="char">82.9 (21.2)</td><td char="(" align="char">&#x02212;0.1 (24.1)</td><td char="(" align="char">84.7 (17.6)</td><td char="(" align="char">&#x02212;4.8 (24.9)</td></tr><tr><td align="left">&#x000a0;Glycemic control</td><td char="(" align="char">80.9 (19.9)</td><td char="(" align="char">6.9 (20.0)</td><td char="(" align="char">78.3 (21.7)</td><td char="(" align="char">10.3 (22.1)</td></tr><tr><td align="left">&#x000a0;Hypoglycemic control</td><td char="(" align="char">85.5 (14.7)</td><td char="(" align="char">&#x02212;2.7 (17.7)</td><td char="(" align="char">85.7 (17.8)</td><td char="(" align="char">0.1 (17.0)</td></tr><tr><td align="left">&#x000a0;Insulin delivery device satisfaction</td><td char="(" align="char">86.9 (15.7)</td><td char="(" align="char">4.2 (16.1)</td><td char="(" align="char">88.6 (14.3)</td><td char="(" align="char">1.1 (10.6)</td></tr><tr><td align="left">&#x000a0;Total score</td><td char="(" align="char">86.5 (11.4)</td><td char="(" align="char">1.1 (11.6)</td><td char="(" align="char">86.8 (12.4)</td><td char="(" align="char">1.2 (10.6)</td></tr><tr><td align="left" colspan="5">PAM-D21, mean (SD)</td></tr><tr><td align="left">&#x000a0;Convenience/flexibility</td><td char="(" align="char">90.0 (16.0)</td><td char="(" align="char">&#x02212;0.7 (21.2)</td><td char="(" align="char">91.7 (13.8)</td><td char="(" align="char">&#x02212;1.2 (16.8)</td></tr><tr><td align="left">&#x000a0;Perceived effectiveness</td><td char="(" align="char">74.6 (20.7)</td><td char="(" align="char">5.9 (23.7)</td><td char="(" align="char">72.0 (20.5)</td><td char="(" align="char">12.0 (25.4)</td></tr><tr><td align="left">&#x000a0;Emotional effects</td><td char="(" align="char">84.2 (20.2)</td><td char="(" align="char">1.0 (21.7)</td><td char="(" align="char">86.8 (17.5)</td><td char="(" align="char">&#x02212;0.2 (22.4)</td></tr><tr><td align="left">&#x000a0;Physical effects</td><td char="(" align="char">87.0 (13.4)</td><td char="(" align="char">1.0 (12.8)</td><td char="(" align="char">90.5 (12.9)</td><td char="(" align="char">1.1 (10.4)</td></tr></tbody></table><table-wrap-foot><p>
<italic>IGL</italic>&#x000a0;once-daily basal insulin glargine plus once-daily prandial insulin lispro, <italic>ITSQ</italic>&#x000a0;insulin treatment satisfaction questionnaire, <italic>LM25</italic>&#x000a0;75&#x000a0;% insulin lispro protamine suspension and 25&#x000a0;% insulin lispro solution, <italic>PAM-D21</italic>&#x000a0;perceptions about medications-diabetes 21, <italic>SD</italic>&#x000a0;standard deviation</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec14"><title>Discussion</title><p>To our knowledge, this is the first report to disclose results from a Latin American subpopulation in a study comparing a twice-daily premixed insulin regimen with a once-daily basal insulin plus once-daily prandial insulin regimen in patients with T2DM not adequately controlled on insulin glargine with metformin and/or pioglitazone. One important aspect to highlight is the inclusion of patients &#x02018;failing&#x02019; on insulin glargine plus oral medication, defined as FPG&#x000a0;&#x0003c;121&#x000a0;mg/dL with high HbA1c, meaning that prandial intensification was likely needed. In these patients, further titration of insulin glargine may increase the risk of hypoglycemia. While we did not make any statistical comparisons in this post hoc analysis due to the limited sample size, numerical improvements in HbA1c after 24&#x000a0;weeks, likely to be clinically relevant, were observed with both LM25 and IGL. Our approach is consistent with the ALAD guidelines for intensifying insulin therapy in patients with HbA1c&#x000a0;&#x0003e;7.0&#x000a0;% and our results suggest that both LM25 and IGL can be effective for lowering HbA1c in Latin American patients with T2DM who have blood glucose levels not adequately controlled on oral agents and basal insulin.</p><p>The reduction in HbA1c levels after 24&#x000a0;weeks of treatment experienced by both groups in the Latin American subpopulation is consistent with, and numerically higher than, the trial-level results in participants of various countries and ethnicities, which showed LM25 to be noninferior, and subsequently superior, to IGL with respect to glycemic control as measured by the change in HbA1c over the 24-week treatment period [<xref ref-type="bibr" rid="CR12">12</xref>]. In keeping with the primary efficacy finding, improvements in secondary efficacy outcomes, including the proportion of participants who achieved HbA1c targets and SMBG, were also observed in the 2 study groups in the Latin American subpopulation. The secondary efficacy outcome results are also consistent with the trial-level findings [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Our observation that FPG increased and HbA1c decreased from baseline in both treatment groups appears somewhat paradoxical. This phenomenon was numerically greater in the LM25 group. Findings from a previous study suggested that the relative contribution of postprandial glucose to HbA1c increases as glycemic control improves, whereas the contribution of FPG increases as diabetes worsens [<xref ref-type="bibr" rid="CR16">16</xref>]. Based on FPG, the patients in this study were already optimized on glargine, therefore, the benefit was most likely due to the postprandial component with both intensification strategies.</p><p>We observed a trend for numerically lower blood glucose concentrations before lunch in the LM25 group compared with the IGL group. This difference in before-lunch blood glucose was also observed at a numerically lower level in the trial-level results [<xref ref-type="bibr" rid="CR12">12</xref>]. Interestingly, in another study (DURABLE), Hispanic participants had significantly lower postprandial glucose after breakfast compared with the Caucasian participants [<xref ref-type="bibr" rid="CR17">17</xref>]. Patients in Latin America vary with respect to the timing of their main daily meal. LM25 was administered before morning and evening meals in both our study and the DURABLE trial, regardless of when the main meal was consumed. Administering LM25 and then consuming a small meal, or a meal with high levels of dietary fiber or a low glycemic index at breakfast time, as is common in Argentina, could account for the lower blood glucose concentrations observed in Hispanic and Latin American participants [<xref ref-type="bibr" rid="CR18">18</xref>]. Conversely, consuming only breakfast and dinner, as is common in Mexico, may also result in low blood glucose during the day; however, administering LM25 at breakfast and dinner in this situation could be appropriate. Importantly, a recently published subanalysis of the trial-level results demonstrated that glycemic control improved in patients receiving either LM25 or IGL, regardless of the timing of the main daily meal [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Despite the lower blood glucose concentrations before lunch with LM25 and the general concern that premixed insulin may increase the risk of hypoglycemia [<xref ref-type="bibr" rid="CR20">20</xref>], we found that, while the rates of hypoglycemia in the Latin American subpopulation were numerically higher than those observed in the trial-level population [<xref ref-type="bibr" rid="CR12">12</xref>], both the incidence and rate of hypoglycemia during the study were similar between the 2 study groups. It is important to note that these similar rates of hypoglycemia were observed in the context of a 0.5&#x000a0;% difference in HbA1c. Only 1 participant experienced severe hypoglycemia and this did not result in a discontinuation. The numerically higher overall rate of hypoglycemia may be explained by specific dietary patterns, exercise habits, or cultural practices in the Latin American population. It is also notable that the mean insulin dose was numerically higher in this Latin American population compared with the trial population [<xref ref-type="bibr" rid="CR12">12</xref>]. This higher dose may have contributed to the numerically higher rates of hypoglycemia observed in this analysis.</p><p>We also found that participants in the LM25 group gained more weight over the 24-week treatment period than participants in the IGL group. This trend was also observed in the trial-level results (LM25&#x000a0;=&#x000a0;1.13&#x000a0;kg, IGL&#x000a0;=&#x000a0;0.50&#x000a0;kg) [<xref ref-type="bibr" rid="CR12">12</xref>]; however, the difference between treatments was more pronounced in the Latin American subgroup. One reason for this may be that patients can overeat to avoid hypoglycemia, particularly in cases where a frugal breakfast is eaten, which is often the case in Argentina and Brazil. Our finding of increased weight gain with LM25 should be considered within the broader context of improved glycemic control and the absence of specific recommendation for the management of diet and exercise in the management of weight in patients with T2DM [<xref ref-type="bibr" rid="CR11">11</xref>]. The numerically higher insulin dose observed in this Latin American subpopulation compared with the trial-level population [<xref ref-type="bibr" rid="CR12">12</xref>] may also have contributed to the weight gain observed in this analysis.</p><p>This subanalysis of a multinational study has a number of strengths, including the prospective, multisite, multicountry, randomized design and the Latin American study population, which permits the exploration of the efficacy of insulin regimens in patients with varied meal patterns. As with most clinical trials of insulin, our study also has a number of limitations including: the post hoc nature of the analysis and open-label design of the study; the fact that the 2 insulin regimens used different injection devices and had different dosing requirements; the fixed distribution of doses at breakfast and dinner, which may have been better given at different times in some regions; and the relatively small sample size in each of the 3 Latin American countries. The study was not powered to compare the ethnic subgroups within the study population and, therefore, no statistical comparisons were made between groups. The differences in prescribing practices, dietary habits, and clinical guidelines among Latin American countries mean that the results of this post hoc analysis may not be generalizable to other Latin American countries.</p></sec><sec id="Sec15"><title>Conclusions</title><p>Intensification of insulin therapy with either LM25 or IGL improved HbA1c in Latin American patients with T2DM who had not achieved target HbA1c on once-daily basal insulin glargine with metformin and/or pioglitazone. The overall safety profile was similar between groups. The results of this study add to the body of evidence that supports the current ALAD guidelines, which recommend both insulin regimens as an option for insulin intensification in patients who do not achieve target HbA1c on basal insulin with oral antidiabetic drugs.
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ALAD</term><def><p>Latin American Diabetes Association</p></def></def-item><def-item><term>FPG</term><def><p>fasting plasma glucose</p></def></def-item><def-item><term>HbA1c</term><def><p>glycated hemoglobin</p></def></def-item><def-item><term>IGL</term><def><p>once-daily basal insulin glargine plus once-daily prandial insulin lispro</p></def></def-item><def-item><term>ITSQ</term><def><p>insulin treatment satisfaction questionnaire</p></def></def-item><def-item><term>ITT</term><def><p>intent-to-treat</p></def></def-item><def-item><term>LM25</term><def><p>insulin lispro low mixture; 75&#x000a0;% insulin lispro protamine suspension and 25&#x000a0;% insulin lispro solution</p></def></def-item><def-item><term>PAM-D21</term><def><p>perceptions about medications-diabetes 21</p></def></def-item><def-item><term>SD</term><def><p>standard deviation</p></def></def-item><def-item><term>SMBG</term><def><p>self-monitoring of blood glucose</p></def></def-item><def-item><term>T2DM</term><def><p>type 2 diabetes mellitus</p></def></def-item><def-item><term>TEAE</term><def><p>treatment-emergent adverse event</p></def></def-item></def-list></glossary><ack><title>Authors&#x02019; contributions</title><p>All authors participated in the interpretation of study results, and in the drafting, critical revision, and approval of the final version of the manuscript. AR (Angel) was involved in the study design and AR (Arturo), GS, and JLG were investigators and were involved in data collection. RD was involved in statistical analysis. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p>None.</p></sec><sec id="FPar2"><title>Competing interests</title><p>DB and JM are employees of Eli Lilly do Brasil Ltda. RD is an employee of Eli Lilly and Company. BL is an employee of Eli Lilly Interamerica Inc. OS is an employee of Eli Lilly and Co. AR (Angel) is an employee of Lilly Spain. DB owns equity in Eli Lilly do Brasil Ltda. AR (Angel) owns equity in Lilly Spain. JLG, GS, and AR (Arturo) have no competing interests to declare.</p></sec><sec id="FPar3"><title>Funding support</title><p>This study was sponsored by Eli Lilly and Company, manufacturer/licensee of insulin lispro low mixture and insulin lispro. Medical writing assistance was provided by Elise Magatova, Ph.D. and Luke Carey, Ph.D. of ProScribe&#x02013;Envision Pharma Group, and was funded by Eli Lilly and Company. ProScribe&#x02019;s services complied with international guidelines for Good Publication Practice (GPP3).</p><p>Eli Lilly and Company was involved in the study design, data collection, data analysis, and preparation of the manuscript.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">International Diabetes Federation. IDF Diabetes Atlas. 6th ed; 2013. <ext-link ext-link-type="uri" xlink:href="http://www.idf.org/diabetesatlas">http://www.idf.org/diabetesatlas</ext-link>. Accessed 18 May 2015.</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">International Diabetes Federation. IDF Diabetes Atlas. 6th ed; 2014. <ext-link ext-link-type="uri" xlink:href="http://www.idf.org/diabetesatlas">http://www.idf.org/diabetesatlas</ext-link>. Accessed 18 May 2015.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzman</surname><given-names>JR</given-names></name><name><surname>Lyra</surname><given-names>R</given-names></name><name><surname>Aguilar-Salinas</surname><given-names>CA</given-names></name><name><surname>Cavalcanti</surname><given-names>S</given-names></name><name><surname>Escano</surname><given-names>F</given-names></name><name><surname>Tambasia</surname><given-names>M</given-names></name><etal/></person-group><article-title>Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association</article-title><source>Rev Panam Salud Publica</source><year>2010</year><volume>28</volume><fpage>463</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1590/S1020-49892010001200008</pub-id><pub-id pub-id-type="pmid">21308173</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>JA</given-names></name><name><surname>Barquera</surname><given-names>S</given-names></name><name><surname>Gonzalez-Cossio</surname><given-names>T</given-names></name><name><surname>Olaiz</surname><given-names>G</given-names></name><name><surname>Sepulveda</surname><given-names>J</given-names></name></person-group><article-title>Nutrition transition in Mexico and in other Latin American countries</article-title><source>Nutr Rev</source><year>2004</year><volume>62</volume><fpage>S149</fpage><lpage>S157</lpage><pub-id pub-id-type="doi">10.1111/j.1753-4887.2004.tb00086.x</pub-id><pub-id pub-id-type="pmid">15387482</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romieu</surname><given-names>I</given-names></name><name><surname>Hernandez-Avila</surname><given-names>M</given-names></name><name><surname>Rivera</surname><given-names>JA</given-names></name><name><surname>Ruel</surname><given-names>MT</given-names></name><name><surname>Parra</surname><given-names>S</given-names></name></person-group><article-title>Dietary studies in countries experiencing a health transition: Mexico and Central America</article-title><source>Am J Clin Nutr</source><year>1997</year><volume>65</volume><fpage>1159S</fpage><lpage>1165S</lpage><pub-id pub-id-type="pmid">9094914</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JC</given-names></name><name><surname>Gagliardino</surname><given-names>JJ</given-names></name><name><surname>Baik</surname><given-names>SH</given-names></name><name><surname>Chantelot</surname><given-names>JM</given-names></name><name><surname>Ferreira</surname><given-names>SR</given-names></name><name><surname>Hancu</surname><given-names>N</given-names></name><etal/></person-group><article-title>Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS)</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>227</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.2337/dc08-0435</pub-id><pub-id pub-id-type="pmid">19033410</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viana</surname><given-names>LV</given-names></name><name><surname>Leitao</surname><given-names>CB</given-names></name><name><surname>Kramer</surname><given-names>CK</given-names></name><name><surname>Zucatti</surname><given-names>AT</given-names></name><name><surname>Jezini</surname><given-names>DL</given-names></name><name><surname>Felicio</surname><given-names>J</given-names></name><etal/></person-group><article-title>Poor glycaemic control in Brazilian patients with type 2 diabetes attending the public healthcare system: a cross-sectional study</article-title><source>BMJ Open.</source><year>2013</year><volume>3</volume><fpage>e003336</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2013-003336</pub-id><pub-id pub-id-type="pmid">24052610</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holman</surname><given-names>RR</given-names></name><name><surname>Paul</surname><given-names>SK</given-names></name><name><surname>Bethel</surname><given-names>MA</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Neil</surname><given-names>HA</given-names></name></person-group><article-title>10-year follow-up of intensive glucose control in type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>1577</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0806470</pub-id><pub-id pub-id-type="pmid">18784090</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>K</given-names></name><name><surname>Chiodini</surname><given-names>P</given-names></name><name><surname>Bellastella</surname><given-names>G</given-names></name><name><surname>Maiorino</surname><given-names>MI</given-names></name><name><surname>Giugliano</surname><given-names>D</given-names></name></person-group><article-title>Proportion of patients at HbA1c target&#x000a0;&#x0003c;7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients</article-title><source>Diabetes Obes Metab</source><year>2012</year><volume>14</volume><fpage>228</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2011.01512.x</pub-id><pub-id pub-id-type="pmid">21958121</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>DR</given-names></name></person-group><article-title>Stepwise intensification of insulin therapy in type 2 diabetes management&#x02014;exploring the concept of the basal-plus approach in clinical practice</article-title><source>Diabet Med</source><year>2013</year><volume>30</volume><fpage>276</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1111/dme.12019</pub-id><pub-id pub-id-type="pmid">22998363</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzucchi</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Diamant</surname><given-names>M</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><etal/></person-group><article-title>Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><fpage>1364</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.2337/dc12-0413</pub-id><pub-id pub-id-type="pmid">22517736</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tinahones</surname><given-names>FJ</given-names></name><name><surname>Gross</surname><given-names>JL</given-names></name><name><surname>Onaca</surname><given-names>A</given-names></name><name><surname>Cleall</surname><given-names>S</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name></person-group><article-title>Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial</article-title><source>Diabetes Obes Metab</source><year>2014</year><volume>16</volume><fpage>963</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1111/dom.12303</pub-id><pub-id pub-id-type="pmid">24725616</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. In: WHO, editors. World Health Organization, Department of Noncommunicable Diseases Surveillance, Geneva, Switzerland. Document WHO/NCD/NCS/99.2. 1999. <ext-link ext-link-type="uri" xlink:href="https://www.staff.ncl.ac.uk/philip.home/who_dmc.htm">https://www.staff.ncl.ac.uk/philip.home/who_dmc.htm</ext-link>. Accessed 20 May 2015.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>RT</given-names></name><name><surname>Skovlund</surname><given-names>SE</given-names></name><name><surname>Marrero</surname><given-names>D</given-names></name><name><surname>Levine</surname><given-names>DW</given-names></name><name><surname>Meadows</surname><given-names>K</given-names></name><name><surname>Brod</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development and validation of the insulin treatment satisfaction questionnaire</article-title><source>Clin Ther</source><year>2004</year><volume>26</volume><fpage>565</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1016/S0149-2918(04)90059-8</pub-id><pub-id pub-id-type="pmid">15189754</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monahan</surname><given-names>PO</given-names></name><name><surname>Lane</surname><given-names>KA</given-names></name><name><surname>Hayes</surname><given-names>RP</given-names></name><name><surname>McHorney</surname><given-names>CA</given-names></name><name><surname>Marrero</surname><given-names>DG</given-names></name></person-group><article-title>Reliability and validity of an instrument for assessing patients&#x02019; perceptions about medications for diabetes: the PAM-D</article-title><source>Qual Life Res</source><year>2009</year><volume>18</volume><fpage>941</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1007/s11136-009-9510-2</pub-id><pub-id pub-id-type="pmid">19609723</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monnier</surname><given-names>L</given-names></name><name><surname>Lapinski</surname><given-names>H</given-names></name><name><surname>Colette</surname><given-names>C</given-names></name></person-group><article-title>Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><fpage>881</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.3.881</pub-id><pub-id pub-id-type="pmid">12610053</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>JA</given-names></name><name><surname>Wolffenbuttel</surname><given-names>BH</given-names></name><name><surname>Arakaki</surname><given-names>RF</given-names></name><name><surname>Caballero</surname><given-names>AE</given-names></name><name><surname>Jiang</surname><given-names>HH</given-names></name><name><surname>Hardin</surname><given-names>DS</given-names></name></person-group><article-title>Impact of race/ethnicity on efficacy and safety of two starter insulin regimens in patients with type 2 diabetes: a posthoc analysis of the DURABLE trial</article-title><source>Ethn Dis</source><year>2013</year><volume>23</volume><fpage>393</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">24392599</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>FM</given-names></name><name><surname>Kramer</surname><given-names>CK</given-names></name><name><surname>Crispim</surname><given-names>D</given-names></name><name><surname>Azevedo</surname><given-names>MJ</given-names></name></person-group><article-title>A high-glycemic index, low-fiber breakfast affects the postprandial plasma glucose, insulin, and ghrelin responses of patients with type 2 diabetes in a randomized clinical trial</article-title><source>J Nutr</source><year>2015</year><volume>145</volume><fpage>736</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.3945/jn.114.195339</pub-id><pub-id pub-id-type="pmid">25833777</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Gross JL, Rojas A, Shah S, Tinahones FJ, Cleall S, Rodr&#x000ed;guez A. Insulin lispro mix 25/75 twice daily (LM25 BID) vs basal insulin glargine&#x000a0;+&#x000a0;prandial insulin lispro both once daily (IGL) in type 2 diabetes (T2D): analysis based on the main meal. IDF-WPR (2014) International Diabetes Federation&#x02014;10th Western Pacific Region Congress. Singapore; 2014.</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riddle</surname><given-names>MC</given-names></name><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Vlajnic</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name></person-group><article-title>Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections</article-title><source>Diabetes Obes Metab</source><year>2014</year><volume>16</volume><fpage>396</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1111/dom.12225</pub-id><pub-id pub-id-type="pmid">24118931</pub-id></element-citation></ref></ref-list></back></article>